The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1
Open accessAbstract
Recent cross-sectional analyses of HIV-1+ plasmas have indicated that broadly cross-reactive neutralizing antibody responses are developed by 10%-30% of HIV-1+ subjects. The timing of the initial development of such anti-viral responses is unknown. It is also unknown whether the emergence of these responses coincides with the appearance of antibody specificities to a single or multiple regions of the viral envelope glycoprotein (Env). Here we analyzed the cross-neutralizing antibody responses in longitudinal plasmas collected soon after and up to seven years after HIV-1 infection. We find that anti-HIV-1 cross-neutralizing antibody responses first become evident on average at 2.5 years and, in rare cases, as early as 1 year following infection. If cross-neutralizing antibody responses do not develop during the first 2-3 years of infection, they most likely will not do so subsequently. Our results indicate a potential link between the development of cross-neutralizing antibody responses and specific activation markers on T cells, and with plasma viremia levels. The earliest cross-neutralizing antibody response targets a limited number of Env regions, primarily the CD4-binding site and epitopes that are not present on monomeric Env, but on the virion-associated trimeric Env form. In contrast, the neutralizing activities of plasmas from subjects that did not develop cross-neutralizing antibody responses target epitopes on monomeric gp120 other than the CD4-BS. Our study provides information that is not only relevant to better understanding the interaction of the human immune system with HIV but may guide the development of effective immunization protocols. Since antibodies to complex epitopes that are present on the virion-associated envelope spike appear to be key components of earliest cross-neutralizing activities of HIV-1+ plasmas, then emphasis should be made to elicit similar antibodies by vaccination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Walker, L. M., Phogat, S. K., Chan-Hui, P.-Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T., Simek, M. D., Fling, S., Mitcham, J. L., et al. (2009) · Science · doi:10.1126/science.1178746 · Cited by 1,723
Nurieva, R. I., Chung, Y., Hwang, D., Yang, X. O., Kang, H. S., Ma, L., Wang, Y.-H., Watowich, S. S., Jetten, A. M., Tian, Q., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.05.009 · Cited by 1,205
Rapid evolution of the neutralizing antibody response to HIV type 1 infection
Richman, D. D., Wrin, T., Little, S. J., & Petropoulos, C. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630530100 · Cited by 1,200
Trkola, A., Purtscher, M., Muster, T., Ballaun, C., Buchacher, A., Sullivan, N., Srinivasan, K., Sodroski, J., Moore, J. P., & Katinger, H. (1996) · Journal of Virology · doi:10.1128/jvi.70.2.1100-1108.1996 · Cited by 1,114
Li, M., Gao, F., Mascola, J. R., Stamatatos, L., Polonis, V. R., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P., Greene, K. M., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.16.10108-10125.2005 · Cited by 1,070
Self-citationBroad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
Scheid, J. F., Mouquet, H., Feldhahn, N., Seaman, M. S., Velinzon, K., Pietzsch, J., Ott, R. G., Anthony, R. M., Zebroski, H., Hurley, A., et al. (2009) · Nature · doi:10.1038/nature07930 · Cited by 867
Deeks, S. G., Kitchen, C. M. R., Liu, L., Guo, H., Gascon, R., Narváez, A. B., Hunt, P., Martin, J. N., Kahn, J. O., Levy, J., et al. (2004) · Blood · doi:10.1182/blood-2003-09-3333 · Cited by 804
Zwick, M. B., Labrijn, A. F., Wang, M., Spenlehauer, C., Saphire, E. O., Binley, J. M., Moore, J. P., Stiegler, G., Katinger, H., Burton, D. R., et al. (2001) · Journal of Virology · doi:10.1128/jvi.75.22.10892-10905.2001 · Cited by 797
Chtanova, T., Tangye, S. G., Newton, R., Frank, N., Hodge, M. R., Rolph, M. S., & Mackay, C. R. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.1.68 · Cited by 722
Binley, J. M., Wrin, T., Korber, B., Zwick, M. B., Wang, M., Chappey, C., Stiegler, G., Kunert, R., Zolla-Pazner, S., Katinger, H., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.23.13232-13252.2004 · Cited by 705
Cited by
Vinuesa, C. G., Linterman, M. A., Yu, D., & MacLennan, I. C. M. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055605 · Cited by 1,141
Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding
Scheid, J. F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T. Y. K., Pietzsch, J., Fenyo, D., Abadir, A., Velinzon, K., et al. (2011) · Science · doi:10.1126/science.1207227 · Cited by 1,139
Klein, F., Diskin, R., Scheid, J. F., Gaebler, C., Mouquet, H., Georgiev, I. S., Pancera, M., Zhou, T., Incesu, R.-B., Fu, B. Z., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.018 · Cited by 537
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals
Caskey, M., Schoofs, T., Gruell, H., Settler, A., Karagounis, T., Kreider, E. F., Murrell, B., Pfeifer, N., Nogueira, L., Oliveira, T. Y., et al. (2017) · Nature Medicine · doi:10.1038/nm.4268 · Cited by 487
HIV‐1 neutralizing antibodies: understanding nature's pathways
Mascola, J. R., & Haynes, B. F. (2013) · Immunological Reviews · doi:10.1111/imr.12075 · Cited by 475
Broadly Neutralizing Antiviral Antibodies
Corti, D., & Lanzavecchia, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095916 · Cited by 475
Gray, E. S., Madiga, M. C., Hermanus, T., Moore, P. L., Wibmer, C. K., Tumba, N. L., Werner, L., Mlisana, K., Sibeko, S., Williamson, C., et al. (2011) · Journal of Virology · doi:10.1128/jvi.00198-11 · Cited by 466
Antibodies in HIV-1 Vaccine Development and Therapy
Klein, F., Mouquet, H., Dosenovic, P., Scheid, J. F., Scharf, L., & Nussenzweig, M. C. (2013) · Science · doi:10.1126/science.1241144 · Cited by 457
Human Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies
Kwong, P. D., & Mascola, J. R. (2012) · Immunity · doi:10.1016/j.immuni.2012.08.012 · Cited by 455
Bonsignori, M., Hwang, K.-K., Chen, X., Tsao, C.-Y., Morris, L., Gray, E., Marshall, D. J., Crump, J. A., Kapiga, S. H., Sam, N. E., et al. (2011) · Journal of Virology · doi:10.1128/jvi.05045-11 · Cited by 423
Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design
Diskin, R., Scheid, J. F., Marcovecchio, P. M., West, A. P., Klein, F., Gao, H., Gnanapragasam, P. N. P., Abadir, A., Seaman, M. S., Nussenzweig, M. C., et al. (2011) · Science · doi:10.1126/science.1213782 · Cited by 375
Bonsignori, M., Pollara, J., Moody, M. A., Alpert, M. D., Chen, X., Hwang, K.-K., Gilbert, P. B., Huang, Y., Gurley, T. C., Kozink, D. M., et al. (2012) · Journal of Virology · doi:10.1128/jvi.01023-12 · Cited by 375
A Blueprint for HIV Vaccine Discovery
Burton, D. R., Ahmed, R., Barouch, D. H., Butera, S. T., Crotty, S., Godzik, A., Kaufmann, D. E., McElrath, M. J., Nussenzweig, M. C., Pulendran, B., et al. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.09.008 · Cited by 375
Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
Haynes, B. F., Wiehe, K., Borrow, P., Saunders, K. O., Korber, B., Wagh, K., McMichael, A. J., Kelsoe, G., Hahn, B. H., Alt, F., et al. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00753-w · Cited by 352
Targeting the Latent Reservoir for HIV-1
Sengupta, S., & Siliciano, R. F. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.030 · Cited by 340
Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning
Kwong, P. D., Mascola, J. R., & Nabel, G. J. (2013) · Nature Reviews Immunology · doi:10.1038/nri3516 · Cited by 329
Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy
West, A. P., Scharf, L., Scheid, J. F., Klein, F., Bjorkman, P. J., & Nussenzweig, M. C. (2014) · Cell · doi:10.1016/j.cell.2014.01.052 · Cited by 321
HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1
Schoofs, T., Klein, F., Braunschweig, M., Kreider, E. F., Feldmann, A., Nogueira, L., Oliveira, T., Lorenzi, J. C. C., Parrish, E. H., Learn, G. H., et al. (2016) · Science · doi:10.1126/science.aaf0972 · Cited by 313
McGuire, A. T., Hoot, S., Dreyer, A. M., Lippy, A., Stuart, A., Cohen, K. W., Jardine, J., Menis, S., Scheid, J. F., West, A. P., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20122824 · Cited by 309
“S. Hoot’s present address is Altravax, Inc. Sunnyvale, CA 94085.”
Self-citationLandais, E., Huang, X., Havenar-Daughton, C., Murrell, B., Price, M. A., Wickramasinghe, L., Ramos, A., Bian, C. B., Simek, M., Allen, S., et al. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005369 · Cited by 265
Metadata
- Authors
- Mikell, I., Sather, D. N., Kalams, S. A., Altfeld, M., Alter, G., & Stamatatos, L.
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-01-13
- Volume
- 7
- Issue
- 1
- Pages
- e1001251
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- OpenAlex
- W1974273518
- Cited by
- 315
- References
- 45
- FWCI
- 14.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.